Type 1 autoimmune pancreatitis by Zen, Yoh et al.
REVIEW Open Access
Type 1 autoimmune pancreatitis
Yoh Zen
1*, Dimitrios P Bogdanos
1 and Shigeyuki Kawa
2
Abstract
Before the concept of autoimmune pancreatitis (AIP) was established, this form of pancreatitis had been
recognized as lymphoplasmacytic sclerosing pancreatitis or non-alcoholic duct destructive chronic pancreatitis
based on unique histological features. With the discovery in 2001 that serum IgG4 concentrations are specifically
elevated in AIP patients, this emerging entity has been more widely accepted. Classical cases of AIP are now called
type 1 as another distinct subtype (type 2 AIP) has been identified. Type 1 AIP, which accounts for 2% of chronic
pancreatitis cases, predominantly affects adult males. Patients usually present with obstructive jaundice due to
enlargement of the pancreatic head or thickening of the lower bile duct wall. Pancreatic cancer is the leading
differential diagnosis for which serological, imaging, and histological examinations need to be considered.
Serologically, an elevated level of IgG4 is the most sensitive and specific finding. Imaging features include irregular
narrowing of the pancreatic duct, diffuse or focal enlargement of the pancreas, a peri-pancreatic capsule-like rim,
and enhancement at the late phase of contrast-enhanced images. Biopsy or surgical specimens show diffuse
lymphoplasmacytic infiltration containing many IgG4
+ plasma cells, storiform fibrosis, and obliterative phlebitis. A
dramatic response to steroid therapy is another characteristic, and serological or radiological effects are normally
identified within the first 2 or 3 weeks. Type 1 AIP is estimated as a pancreatic manifestation of systemic IgG4-
related disease based on the fact that synchronous or metachronous lesions can develop in multiple organs (e.g.
bile duct, salivary/lacrimal glands, retroperitoneum, artery, lung, and kidney) and those lesions are histologically
identical irrespective of the organ of origin. Several potential autoantigens have been identified so far. A Th2-
dominant immune reaction and the activation of regulatory T-cells are assumed to be involved in the underlying
immune reaction. IgG4 antibodies have two unique biological functions, Fab-arm exchange and a rheumatoid
factor-like activity, both of which may play immune-defensive roles. However, the exact role of IgG4 in this disease
still remains to be clarified. It seems important to recognize this unique entity given that the disease is treatable
with steroids.
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Background
The entity “autoimmune pancreatitis (AIP)” was first pro-
posed by Yoshida et al [1] in 1995, who described a case of
steroid-responsive pancreatitis. That report described a
case of a diffuse enlargement of the pancreas and irregular
narrowing of the pancreatic duct, serologically associated
with hyper-g-globulinemia and anti-nuclear antibody
(ANA) positivity [1]. The presence of pancreatitis, features
of autoimmune disease, and responsiveness to immunosu-
pression led to the connotation of AIP [1]. The term of
AIP has been since used by other groups, and is now
accepted worldwide. However, the first evidence of
features compatible with AIP was described by Sarles et al
[2]. in 1961, who reported the case series of an unusual
pancreatitis associated with obstructive jaundice and
hyper-g-globulinemia, suggestive of an underlying autoim-
mune process. This form of pancreatitis was recognized as
lymphoplasmacytic sclerosing pancreatitis or non-alco-
holic duct destructive chronic pancreatitis based on dis-
tinct histological features in the 1990s [3,4]. Another
landmark paper was published in the New England Journal
of Medicine in 2001, where Hamano et al [5]. reported
that serum IgG4 levels are specifically elevated in Japanese
patients with AIP. An increase of IgG4 levels in AIP
cohorts has been also confirmed in Western and Eastern
countries [6,7]. The discovery of hyper-IgG4 has strength-
ened the concept of AIP. In addition, clinical and histolo-
gical reviews of AIP patients provided evidence that AIP
* Correspondence: yoh.zen@kcl.ac.uk
1Institute of Liver Studies, King’s College Hospital and King’s College London
School of Medicine, Denmark Hill, London SE5 9RS, UK
Full list of author information is available at the end of the article
Zen et al. Orphanet Journal of Rare Diseases 2011, 6:82
http://www.ojrd.com/content/6/1/82
© 2011 Zen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.can be classified into 2 types: IgG4-related and non-related
[8,9].
IgG4 is not only a serological marker but is also histolo-
gically detectable. The demonstration of pancreatic infil-
tration by IgG4
+ plasma cells reported in 2002 [10] was
followed by studies reporting similar sclerosing lesions in
various organs [11,12]. Hence, a new systemic disease
entity, “IgG4-related disease”, is proposed. This is based
on the fact that synchronous or metachronous lesions can
develop in multiple organs and the lesions are histologi-
cally identical irrespective of the organ of origin [13,14].
IgG4-related AIP is considered a pancreatic manifestation
of IgG4-related disease.
Subtypes and histopathology of AIP
Recent papers have provided evidence that there are two
subtypes of AIP with different clinical and histological
characteristics [8,9,15,16]. The classical form is called
type 1 AIP, which is associated with elevated serum
IgG4 levels and tissue infiltration by IgG4
+ plasma cells
[15,16]. Type 2 AIP, which is not related to IgG4, was
identified based on the histological features of neutro-
philic infiltration into the pancreatic duct epithelium
(granulocytic epithelial lesion: GEL) [17,18]. Type 1
appears to be the most predominant form of AIP. Clini-
cal and histological features of both subtypes are sum-
marized in Table 1. A Japanese nationwide study
revealed that the annual number of patients with type 1
AIP is 0.71 per 100,000, which accounts for 2% of
patients with chronic pancreatitis [19]. The exact preva-
lence of type 2 AIP is still unknown but it is less com-
mon than that of type 1 AIP [9,15].
Type 1 and type 2 AIP share some histological features
including diffuse lymphoplasmacytic infiltration and
fibrosis, but these are classifiable based on purely histolo-
gical grounds [17,18,20]. The pathological synonym of
type 1 AIP is lymphoplasmacytic sclerosing pancreatitis
(LPSP) which is characterized by a predominantly lobular
involvement with “storiform” fibrosis, obliterative phlebi-
tis, and infiltration by many IgG4
+ plasma cells (Figure
1A-D) [3,20]. A diagnostic feature of type 2 AIP is GEL
with or without lobular neutrophilic infiltration
[17,18,20]. IgG4
+ plasma cells appear to be less conspicu-
ous in type 2 AIP [21]. That is, the most important histo-
logical feature is IgG4
+ plasma cell infiltration in type 1
and neutrophilic epithelial injury in type 2 AIP. Given
that the clinical features and pathogenesis of type 2 AIP
are poorly defined, this review will only discuss type 1
AIP.
Table 1 Comparison of type 1 and type 2 autoimmune pancreatitis (AIP)
Type 1AIP Type 2 AIP
Age Adult Child and adult
Gender Predominantly male Almost equal
Serum IgG4 levels Elevated Normal
Histology
Histological nomenclature Lymphoplasmacytic sclerosing pancreatitis (LPSP) Idiopathic duct-centric pancreatitis
IgG4
+ plasma cells Many Rare
Granulocytic epithelial lesion Absent Present
Relapse rate High Low
Extra-pancreatic lesions IgG4-related disease as shown in Table 2 Inflammatory bowel disease
Figure 1 Histological and radiological features of type 1 AIP.A :
Pancreas is inflamed with inflammatory cell infiltration and storiform
fibrosis (H&E, ×100). B: Inflammatory cells consist of predominantly
lymphocytes and plasma cells, and occasional eosinophils (H&E,
×400). C: A vein branch is obliterated by sclerosing inflammation
(obliterative phlebitis) (Elastica van Gieson, ×200). D: Many IgG4+
plasma cells are identified (IgG4 immunostaining, ×400). E: ERCP
shows diffuse irregularity of the pancreatic duct. F: The pancreas is
diffusely enlarged with a peri-pancreatic rim (arrows) (contrast-
enhanced CT).
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Type 1 AIP predominantly affects adult males with > 90%
of patients being more than 40 years of age. There is a
male preponderance, with a male/female ratio of 3-4:1
[19,22,23]. The major symptom at onset is obstructive
jaundice, which is caused by an enlargement of the pan-
creatic head or thickening of the bile duct wall [24-26].
Blood tests results include increased bilirubin and chole-
static enzymes, transaminasaemia, and occasionally eleva-
tion of carbohydrate antigen 19-9 (CA19-9) [24]. These
findings mimic those found in pancreatic cancer, and
indeed 2-3% of pancreatic head lesions surgically resected
for suspected malignancy turned out to be type 1 AIP by
histological examination [27,28]. Contrary to pancreatic
cancer, the jaundice of type 1 AIP patients is quickly
improved by steroid therapy or sometimes subsides spon-
taneously. Severe abdominal pain is a rare subjective
symptom different from ordinary chronic pancreatitis,
such as alcoholic pancreatitis [24]. In over half of cases,
levels of pancreatic enzymes are mildly or moderately ele-
vated [24]. Diabetes mellitus is a common complication,
seen in about half of the patients, the majority showing
type II diabetes. Steroid therapy can ameliorate glucose
intolerance in some patients along with an improvement
of pancreatitis, but may aggravate the diabetes in others,
particularly older patients [29,30]. Diarrhoea due to
impaired exocrine function is rare, but bentiromide or
secretin testing shows somewhat impaired exocrine func-
tion [30]. This can be improved to some extent by steroid
therapy [31]. Patients may have symptoms related to
extra-pancreatic lesions such as lacrimal and salivary gland
enlargement [13], cough or dyspnea caused by respiratory
lesions [32], lumbago caused by hydronephrosis and retro-
peritoneal fibrosis [10], and polyuria caused by prostatic
lesions [33-35].
Serological characteristics
Elevated serum levels of IgG4 (> 135 mg/dL) are seen in
more than 90% of patients [5,24]. This is the most sensi-
tive and specific diagnostic test for type 1 AIP, with 95%
sensitivity, 97% specificity, and 97% accuracy for discri-
mination from pancreatic cancer [5]. It is also useful for
determining disease activity and predicting relapse
[36-38]. Other commonly detectable immunological fea-
tures include elevation of IgG (70%), g-globulin (60%),
and IgE (33%) [39,40]. Rheumatoid factor and ANA are
also detectable in 30 to 40% of patients [39,40]. However,
disease-specific autoantibodies such as anti SS-A/Ro and
SS-B/La or anti-mitochondrial antibodies are extremely
uncommon [24]. These findings suggest that patients
with type 1 AIP can produce various autoantibodies but
these antibodies lack disease specificity.
Complement C3 and C4 are reduced in 36% of
patients, particularly those with high levels of circulating
immune complexes, suggesting immune-mediated com-
plement activation [41]. The complement activation sys-
tem consists of classical, alternative, and mannose-
binding lectin pathways. Given that the latter two seem
less activated in type 1 AIP, the classical pathway may
be predominantly operating [41].
The exact role of IgG4 in IgG4-related disease remains
elusive. IgG4-type pathogenic autoantibodies can induce
tissue damage, as in the case of anti-desmoglein 3 autoan-
tibody in pemphigus vulgaris [42]. Few reports regarded
IgG4-type autoantibodies as pathogenic in type 1 AIP.
IgG4 was recently discovered to have two outstanding
characteristics, Fab-arm exchange [43] and rheumatoid
factor-like activity [44], both of which may play immune-
defensive roles by eliminating IgG4-bound immune com-
plex from the circulation. Fab-arm exchange results in bis-
pecific antigen binding, which interferes with the
formation of IgG4-associated immune complexes [44]. It
was also demonstrated that IgG4 can bind to another IgG
of any subclass via Fc-Fc interaction, and this IgG4 Fc-Fc
interaction may represent an intermediate state of the
Fab-arm exchange reaction [44-47], although the role of
this function remains unclear. Further studies are needed
to clarify whether IgG4 has beneficial or detrimental
effects in IgG4-related disease including type 1 AIP.
Radiological features
An important radiological feature is irregular narrowing of
the pancreatic duct which can be detected by endoscopic
retrograde cholangiopancreatography (ERCP) or magnetic
resonance cholangiopancreatography (MRCP) (Figure 1E)
[48,49]. The former is more sensitive but the latter is more
widely used for diagnosis given its less invasive nature.
Complete obliteration of the main pancreatic duct with
dilatation of the distal duct, which is commonly found in
patients with pancreatic cancer, is atypical in type 1 AIP.
Characteristic features of ultrasonography (US), com-
puted tomography (CT) and magnetic resonance imaging
(MRI) include diffuse or focal pancreatic enlargement, a
peri-pancreatic capsule-like rim, enhancement at the late
phase of contrast-enhanced images, and abnormal signal
intensity on MRI [50-52]. Diffuse enlargement of the pan-
creas with loss of the cobble-stone architecture of the pan-
creatic surface is a common finding of type 1 AIP in all
imaging modalities [50-52]. US characteristically shows
diffuse low-echoic change with high-echo spots which was
originally called “sausage-like” swelling [53]. The enlarged
pancreas is associated with a capsule-like, low-density rim
which appears more evident on contrast-enhanced CT or
MRI, particularly at the early phase (Figure 1F) [50-52].
This is a radiological finding representing a fibrosing pro-
cess extending into peri-pancreatic adipose tissue [50]. In
contrast to normal pancreatic parenchyma which shows
enhancement at the early phase of contrast-enhanced
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late phase (a delayed enhancement) [50-52]. Signal inten-
sity of type 1 AIP on T1-weighted MRI is decreased com-
pared to non-affected pancreatic parenchyma, sometimes
appearing even lower than that of the liver [50]. T2-
weighted MRI scans show increased signal intensity. Rare
radiological findings include multiple small nodules [54],
stone formation [55], and cystic degeneration [56], the lat-
ter two being more common at the late stage.
It is also important to identify extra-pancreatic lesions,
t h ep r e s e n c eo fw h i c hi si n dicative of type 1 AIP and
makes a diagnosis of pancreatic cancer less likely. F-18
fluorodeoxyglucose positron emission tomography (FDG-
PET) is also useful for this purpose given that extra-pan-
creatic lesions are usually positive for FDG-PET the same
as type 1 AIP [57-59]. Gallium-67 scintigraphy is another
modality to detect extra-pancreatic lesions, accumulation
at the pulmonary hilum being a characteristic finding for
type 1 AIP patients [60]. In our experience, extra-pancrea-
tic lesions are sometimes detected at unexpected sites by
FDG-PET or systemic CT/MRI.
Diagnosis
A number of diagnostic criteria for type 1 AIP have been
proposed so far from Japan, South Korea, and the United
States (HISORt criteria of the Mayo Clinic) [36,37,61-63].
Despite minor differences among sites, diagnostic criteria
include imaging features, serological abnormalities, and
histological findings. Patients with typical imaging features
(diffuse pancreatic enlargement with an irregular/narrow
pancreatic duct) and elevated serum IgG4 levels, with or
without other non-specific autoimmune abnormalities
(e.g., ANA or hyper-IgG), fulfill all criteria. In a situation
in which serological features cannot be detected, histologi-
cal evidence of LPSP (e.g., diffuse lymphoplasmacytic infil-
tration, storiform fibrosis, and obliterative phlebitis) needs
to be confirmed by biopsies. Immunostaining of IgG4 is
also useful with ≥ 10 IgG4
+ plasma cells per high-power
field in biopsy samples being supportive of LPSP [64].
However, it should be noted that ≥ 10 IgG4
+ plasma cells
can be rarely identified in biopsy specimens from pancrea-
tic cancer [64].
There are still prosa n dcons with steroid trials approved
based on most diagnostic criteria except the Japanese ones
[36,37,61-63]. Given that pancreatic swelling dramatically
improves even after a few weeks of steroid therapy, steroid
trials would be a useful diagnostic test. Immunosupression
must only be considered under restricted conditions, given
that pancreatic cancer is the most likely differential diag-
nosis of type 1 AIP.
Surgically resected specimens showing typical features
of LPSP with numerous IgG4
+ plasma cells can be diag-
nosed as type 1 AIP based purely on histological grounds.
This is particularly important for retrospective reviews of
cases without sufficient serological and radiological data.
It is questionable whether or not findings of a needle
biopsy are sufficient for the diagnosis. If a diagnosis of
type 1 AIP is histologically suggested, imaging and sero-
logical data should be reviewed. In our experience, histo-
logical findings of type 1 AIP in the absence of consistent
radiological or serological features are extremely unlikely.
Treatment
An administration of an oral steroid is a standard treat-
ment for type 1 AIP [65,66]. Most patients respond well to
immunosupression with significant improvement of radi-
ological and serological abnormalities [29,31]. Sponta-
neous remission can also occur particularly in patients
with inactive disease. Normally, patients are started on
3 0 - 4 0m g ,o r0 . 6m g / k g ,p e rd a yo fp r e d n i s o l o n ef o r2 - 4
weeks with careful monitoring of clinical features, and ser-
ological and imaging findings [67,68]. Amelioration of the
clinical features is usually observed within 2 weeks, and
clinical remission is frequently seen within 4 weeks.
Thereafter, the dosage is reduced (tapering by 5 mg/day
every 2 weeks over 2-3 months, to 2.5-7.5 mg per day),
and a maintenance dose is required for 6 months to
3 years [67].
Relapse can be defined as symptomatic or radiologically
detectable disease recurrence in not only the pancreas but
also extrapancreatic organs. Biochemical or serologic
recurrence alone is not considered relapse. Given that
most relapses are observed within the first 3 years, patients
with active disease (e.g. extremely high levels of serum
IgG4 or multiple organ lesions) require prolonged treat-
ment [65-67]. Cessation of maintenance therapy can be
considered after six months in those cases with inactive
disease. If steroid therapy is ineffective, clinical and serolo-
gical data need to be reviewed in order to definitively
exclude pancreatic malignancy. Other therapies which
have been reported to be effective for highly active or
refractory type 1 AIP are steroid pulse therapy [69],
immuno-suppression with azathioprine or 6-mercaptopur-
ine [70], and rituximab administration [71].
Treatment by resection is not recommended for type 1
AIP. However, even in large pancreatic centres, the surgi-
cal approach is still unavoidable for minor cases, for which
malignancy cannot be entirely excluded. Surgeries can be
also considered for large pseudocysts, which are rarely
associated with type 1 AIP [72,73]. Interestingly, one paper
described that recurrent rate after surgery appears lower
than that after steroid therapy [15].
Extra-pancreatic lesions and IgG4-related disease
Type 1 AIP is commonly associated with the involvement
of other organs, the incidence of which was reported to
be approximately 50% to 70% [9,15]. Type 1 AIP is now
considered as a pancreatic manifestation of systemic
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to those seen in the pancreas, can develop in the absence
of pancreatic abnormalities [74,75]. Extra-pancreatic
l e s i o n sm a yb ei d e n t i f i e da tt h es a m et i m ea st y p e1A I P
or may appear afterward particularly during tapering
doses of steroid or after completion of steroid therapy.
As mentioned, extra-pancreatic lesions can precede the
episode of type 1 AIP. IgG4-related disease has been
identified in various organs based on histological evi-
dence of IgG4
+ plasma cell infiltration, steroid respon-
siveness, or high serum IgG4 concentrations. Most IgG4-
related lesions share clinicopathological characteristics
irrespective of the organ of origin, but several organ-
specific features have been identified [76]. As shown in
Table 2 a variety of organs can be involved in IgG4-
related disease. Almost all lesions have probably been
discovered, but the possibility of an IgG4-related disease
always needs to be considered for an unusual lesion at
any site if it appears during the follow up in patients with
known IgG4-related disease.
Pathogenesis
Several genetic susceptibility factors for type 1 AIP have
been identified as summarized in Table 3[77-81]. Findings
obtained in one ethnic group are not always confirmed in
patients in other groups, which raises the possibility that
genetic susceptibility factors may be different among eth-
nic groups.
In view of the autoimmune hypothesis surrounding
IgG4-related disease, a series of studies have investigated
the specificity of autoantibody responses in patients with
type 1 AIP leading to the identification of several autoanti-
gens. Antibodies against lactoferrin and carbonic anhy-
drase (CA) II are most frequently detected in type 1 AIP
(73% and 54%, respectively) [82]. Anti-CA-IV antibodies
were also detected in 34% of patients [83]. Other potential
autoantigens include pancreatic secretory trypsin inhibitor
and trypsinogens [84,85]. However, it remains to be seen
whether IgG4 is an autoantibody in type 1 AIP or is over-
expressed secondary in response to an unknown primary
inflammatory stimulus.
Interestingly, there is significant homology between
human CA-II and alpha-CA of Helicobacter pylori (H.
pylori) [86]. More recently, it was found that 94% of
patients with type 1 AIP had antibodies against plasmino-
gen-binding protein of H. pylori [87]. The amino acid
sequence of this protein exhibits homology with that of
the ubiquitin-protein ligase E3 component n-recognin 2
which is expressed in pancreatic acinar cells. These two
studies raise the possibility that H. pylori infection might
trigger type 1 AIP in genetically predisposed subjects via
molecular mimicry [86,87]. However, the latter study has
reported elevated IgG4 in only 53% of the patients making
it impossible to accurately estimate how many of these
were type 1 AIP [87].
A T-helper (Th) 1 immune response has been consid-
ered to be predominant in type 1 AIP [82]. However,
recent studies provided data in support of a Th2-predo-
minant immune response in IgG4-related disease
[88-92]. In addition, the number of regulatory T-cells
(Tregs) is characteristically increased in tissue-resident
lymphocyte populations and whole blood of patients
with type 1 AIP. The number of CD4
+CD25
high Tregs in
blood was found significantly higher in patients with
type 1 AIP than in patients with chronic pancreatitis
and was correlated with the level of serum IgG4 [93]. In
contrast, the number of naïve Tregs was significantly
decreased. This has led to the assumption that hypo-
reactivity of naïve Tregs may be involved in the develop-
ment of IgG4-related disease, whereas a hyper-reactivity
of CD4
+CD25
high Tregs could reflect IgG4-related dis-
ease progression [93]. Given that IL-10 has a major role
Table 2 A list of major IgG4-related disease in various
organs
Organ Manifestation
Pituitary gland Hypophysitis
Meningis Pachymeningitis
Lacrimal gland Chronic sclerosing dacryoadenitis (Mikulicz’s disease)
Salivary gland Chronic sclerosing sialadenitis (Küttner’s tumour)
Lymph node Lymphadenopathy with 5 histological subtypes
- Multicentric Castleman disease-like (type I)
- Follicular hyperplasia (type II)
- Interfollicular expansion (type III)
- Progressive transformation of germinal centre
(type IV)
- Nodal inflammatory pseudotumor (type V)
Thyroid Thyroiditis or hypothyroidism
Skin Pseudolymphoma
Breast Inflammatory pseudotumour or mastitis
Lung Inflammatory pseudotumour
Focal or diffuse interstitial pneumonia
Inflammation in bronchovascular bundles.
Pleura Nodular pleuritis
Stomach Chronic gastritis or ulcer
Vater’s ampulla Pseudotumourous enlargement
Pancreas Type 1 autoimmune pancreatitis
Bile duct Sclerosing cholangitis
Gallbladder Lymphoplasmacytic sclerosing cholecystitis
Liver Inflammatory pseudotumour
Chronic active hepatitis (autoimmune hepatitis)
Retroperitoneum Retroperitoneal fibrosis
Aorta/artery Periaortitis/periarteritis
Inflammatory aneurysm
Kidney Tubulointerstitial nephritis
Peripheral nerve Perineural mass
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from Th2 cells and Tregs may be involved in hyper-
IgG4 in type 1 AIP [94].
Immune complex deposition is identifiable in the base-
ment membrane of pancreatic ducts and acini [95,96].
These complexes consist of predominantly IgG4 and com-
plement C3, with minor components of other IgG sub-
classes [96,97]. Given that IgG4 cannot form large
immune complexes because of Fab-arm exchange, it
remains to be clarified what is the role of IgG4 in immune
complex formation, and how these depositions are
involved in the pathogenesis of type 1 AIP.
Conclusion
Type 1 AIP is a pancreatic manifestation of IgG4-related
disease. Serological, imaging, and histological examination
are necessary for the diagnosis. Th2-dominant immunity
and activated Tregs are supposed to be important for the
immunopathogensis of the disease. Unique biological
characteristics of IgG4 have been identified, but the exact
role of IgG4 and the relevance of these targets in the
induction of the disease remain to be clarified.
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